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Abstracts / Osteoarthritis and Cartilage 23 (2015) A82eA416 A361Conclusions: A single IA administration of 40 mg of FX006 maintained
pharmacologically active synovial ﬂuid concentrations of TCA for at
least 12 weeks, while TCA IR produced levels that are below the lower
limit of quantitation by 6weeks. These data underpin the differentiation
of FX006 from TCA IR and provide pharmacokinetic basis for previously
demonstrated prolongation and ampliﬁcation of pain relief compared to
TCA IR in OA patients following a single IA injection. FX006 also has the
potential for an improved systemic safety proﬁle as evidenced by peak
plasma concentrations that are 40-fold lower than TCA IR at the same
dose, seen in the aggregate of clinical studies with FX006 to date.
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GASTROINTESTINAL SAFETY AND TOLERABILITY OF LONG-TERM
GCSB-5 OF DRIED EXTRACTS OF SIX HERBS IN PATIENTS WITH
OSTEOARTHRITIS: A 24 WEEKS, MULTI-CENTERS, SINGLE ARM
PHASE IV STUDY
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Purpose: A previous study on GCSB-5 was shown to be non-inferior to
Celecoxib in efﬁcacy and safety in treating osteoarthritis, but its safety
information on the gastrointestinal (GI) safety is limited to only 12weeks.
A longer term (24 weeks) study with a larger number of patients is nec-
essary to establish the GI safety of GCSB-5. The primary goal of this study
was to determine the incidence of GI disorders associated with GCSB-5.
The secondary goal was to collect 24-week safety data of GCSB-5.
Methods: A single arm safety study on 24-week GCSB-5 was conducted.
Additionally, the results of this study were compared with Historical
Data of Celecoxib. This study was performed in 19 academic institutions
between May 2012 and June 2013. Two GCSB-5 capsules (300 mg per
capsule) were prescribed two times per day for 24weeks. Incidence of GI
disorders was the primary outcome. Incidence of GI perforation, ulcer
obstruction and bleeding (PUB), gastroduodenal ulcer, and dropout due
to GI complications were the major secondary outcome variables.
Results: A total of 761 patients with osteoarthritis were enrolled and
756 patients took at least one dose of study drug. A total of 629 patients
(82.7%) completed the 24 weeks follow-up visit. The incidence of GI
disorders among the 756 patients with or without aspirin exposure was
23.7%. Aspirin use did not show any signiﬁcant difference in GI dis-
orders. The annualized incidence rate of PUB was 0.0%. The annualized
incidence rate of gastroduodenal ulcer was 0.0%. The drop-out rate due
to GI disorders in GCSB-5 was 4.8%. As the results compared with His-
torical Data of Celecoxib, the incidence of GI disorders (29.9%),
annualized rate of PUB and gastroduodenal ulcer (2.2%), and drop-out
rate (8.7%) due to GI disorders for Celecoxib were signiﬁcantly higher
than GCSB-5.
Conclusions: This study indicated GCSB-5 was safe for patients with
osteoarthritis during long-term treatment. Furthermore, the safety
results of GCSB-5 associated with GI disorder were comparable to
Celecoxib.
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THE EFFECT OF PREOPERATIVE PAIN TREATMENT BY MEANS OF
DULOXETINE ON POSTOPERATIVE OUTCOME AFTER TOTAL HIP OR
KNEE ARTHROPLASTY: DESIGN OF A PRAGMATIC RANDOMIZED
CONTROLLED TRIAL
T. Blikman y, W. Rienstra y, T.M. van Raaij z, S.K. Bulstra y, M. Stevens y,
I. van den Akker-Scheek y. yUniv. Med. Ctr. Groningen, Groningen,
Netherlands; zMartini Hosp. Groningen, Groningen, NetherlandsPurpose: Total joint replacement (TJR) is considered to be one of the
most safe, successful, and cost-effective treatments for advanced
osteoarthritis (OA). However, residual pain seems to be a major factor of
patient’s dissatisfaction following Total Hip Arthroplasty/Total Knee
Arthroplasty (THA/TKA). The proportion of patients suffering from
unfavourable long-term residual pain is relatively high, proportions
ranging from 10 to 34% after knee and 7 to 23% after hip replacement
surgery. Changes within the central nervous system are presumably
accountable for accessory pain ampliﬁcation and sensitization. Cur-
rently there are studies indicating that a preoperative degree of central
sensitisation (CS) is associated with poorer postoperative outcomes and
residual pain. Thus, it could be hypothesized that preoperative treat-
ment of CS could enhance postoperative outcomes. Duloxetine, a
combined serotonin and norepinephrine reuptake inhibitor (SNRI), has
shown to be effective in several chronic pain syndromes, including
knee-OA, in which CS is likely one of the underlying pain mechanisms.
This study aims to evaluate the postoperative effects of preoperative
screening and targeted duloxetine treatment of CS on residual pain,
compared to care as usual.
Methods: This multi-centre, pragmatic, prospective, open-label,
randomized controlled trial (RCT) includes adults which are on the
waiting list for primary THA/TKA, with a possible or likely neuropathic
pain (NP) phenotype at screening (deﬁned by a score >12 point on the
modiﬁed-painDETECT questionnaire), hence this will probably identify
patients who are more likely to experience CS. Patients will be ran-
domly allocated to the preoperative “duloxetine treatment group” (1
week initiation 30 mg/d, 7 weeks 60 mg/d, 2 weeks taper-phase 30 mg/
d) or the “care as usual group” (no speciﬁc preoperative intervention).
The primary endpoint is the degree of postoperative pain 6 months
after THA/TKA, assessed with the pain subscale of the Hip disability/
Knee injury and Osteoarthritis Outcome Score (HOOS/KOOS). Secondary
endpoints, at multiple pre- and postoperative time points (up to 12
months postoperative) will be; pain, neuropathic pain (NP), sensitisa-
tion (pressure pain thresholds, temporal summation), quality of life and
depressive/anxiety symptoms. Furthermore, factors such as perceived
satisfaction and arthroplasty related expectations will be analyzed.
Based on a minimally clinical important difference of 10 points on the
HOOS/KOOS; a total of 118 patients are anticipated to be randomized to
detect a clinical relevant difference (80% power, 20% protocol violators
and/or dropout included).
Results: Data analysis will be conducted on an intention-to-treat basis.
In case of the primary endpoint a Student’s t-test (or a non-parametric
equivalent in case of a skewed distribution) will be used to determine if
there is a difference in pain on the HOOS/KOOS at 6 months post-
operative between the two groups. GEE (Generalized Estimating
Equation) analysis will be used to determine whether there is a differ-
ence on pain between the two groups over time, adjusted for relevant
covariates. The same principles will be used to asses the secondary time
points. A P-value of < 0.05 is considered statistically signiﬁcant.
Conclusions: This study is, as far as we know, the ﬁrst pragmatic RCT
assessing the postoperative effects of a preoperative targeted dulox-
etine treatment in OA-patients suffering from a degree of preoperative
CS (indicated by a possible or likely NP-phenotype). We believe a
pragmatic trial design is valid; hence it mimics the “real life status”,
with a “care as usual” control group, as much as possible. Furthermore,
the endpoints are, unlike placebo controlled explanatory trials, more
focused on the relevancy to everyday life; like hip and knee speciﬁc
pain, function and quality of life. Knowledge gained with this study can




DIFFERENTIAL PROFILING OF SECRETOMES FROM HUMAN
CARTILAGE TO IDENTIFY POTENTIAL EARLY SPECIFIC PROTEIN
BIOMARKERS IN OSTEOARTHRITIS
L. Lourido, V. Calamia, P. Fernandez-Puente, J. Mateos, B. Rocha,
C. Fernandez-Costa, C. Fernandez-Lopez, N. Oreiro, F.J. Blanco,
C. Ruiz-Romero. INIBIC e CHU A Coru~na, A Coru~na, Spain
Purpose: Osteoarthritis (OA) is characterized by the progressive loss of
cartilage structural extracellular matrix (ECM) components. The release
of these proteins from the tissue can vary according to the stage of the
disease and the speciﬁc joint affected. The aim of this study was to
Abstracts / Osteoarthritis and Cartilage 23 (2015) A82eA416A362perform a quantitative proteomics approach to identify and quantify
those proteins released from normal (N) and OA human articular car-
tilages capable of predicting the early stage of hip and knee OA.
Methods: Tissue explants were obtained from the dissection of 4 N and
4 OA cartilages, both from 2 femoral heads and 2 tibial condyles. Among
the OA samples, we differentiated the wounded zones (WZOA) from
those corresponding to the area adjacent to the lesion, or unwounded
zones (UWOA). Cartilage shavings from each donor were cut into 6 mm
discs and three discs/donor were placed into 96-well plates and cul-
tured during 6 days. The conditioned media from each condition (N,
WZOA and UWOA) were collected and their proteins were digested
with trypsin. The resulting peptides were labelled with different iso-
baric tags using the iTRAQ reagents (ABSciex). Then, labelled peptides
from the different conditions were mixed, desalted and separated by
liquid chromatography (LC). The resulting fractions were grouped and
resolved by reversed-phase nano-LC coupled to mass spectrometry
(MS). The identiﬁcation and relative quantiﬁcation of the proteins was
carried out with Protein Pilot 3.0 software.
Results: Globally we were able to identify 186 proteins released from
the cartilage explants. After statistical analysis we found secreted pro-
teins showing differences in abundance (0.7 ratio 1.3, p 0.05)
between the different OA zones (WZOA and UWOA) and N samples
from the different joints. We classiﬁed them into 3 sets of proteins: a
ﬁrst group of proteins modulated speciﬁcally in UWOA sample (early
OA biomarkers); a second group of proteins altered only in WZOA
samples (late OA biomarkers), and ﬁnally a third groupmodiﬁed in both
OA zones (progression biomarkers). Some of these modulated proteins
are common early and progression biomarkers for both hip and knee OA
(table1). Furthermore, we also identiﬁed that the release of cartilage
intermediate layer protein 1 (CILP-1), a protein involved in cartilage
scaffolding, is increased in UWOA from hip OA cartilage but not in
UWOA from knee OA, being a possible early speciﬁc biomarker for hip
OA. This speciﬁc modulation was conﬁrmed by Real-time PCR and
western blot in other human cartilage samples (n¼3).
Conclusions: We describe a novel panel of cartilage-secreted proteins
with potential biomarker value. Interestingly, we have identiﬁed a
speciﬁc protein, which speciﬁcally indicates hip OA onset. This protein
is now being explored in biological ﬂuids (synovial ﬂuid and serum) for
the development of early diagnosis and/or anti-OA therapy monitoring
strategies.Table 1
A panel of different type of potential protein biomarkers of hip OA(H) and knee OA(K) is listed in the table. Proteins showing a gradual increase among OA samples is indicated
as early and progression biomarkers. CLIP-1 speciﬁcally indicates hip OA.
Protein Name Uniprot symbol Joint peptides (95%) Ratio UWOA/N p value Ratio WZOA/N p value OA biomarker type
Pigment epithelium-derived factor PEDF H 25 2,35 0,00 4,73 0,00 Early and progression
K 32 2,31 0,00 3,16 0,00
Tenascin TENA H 60 2,99 0,00 5,03 0,00 Early and progression
K 65 1,68 0,00 6,01 0,00
Tenascin-X TENX H 28 3,21 0,00 6,84 0,00 Early and progression
K 52 1,34 0,02 2,38 0,00
Tetranection TNT H 15 2,63 0,00 3,68 0,00 Early and progression
K 16 1,96 0,01 3,52 0,00
Transforming growth factor-beta
included protein lg-h3
BGH3 H 24 5,34 0,00 6,12 0,00 Early and progression
K 23 1,57 0,00 3,55 0,00
Vimentin VIM H 22 3,69 0,00 5,13 0,00 Early and progression
K 30 1,40 0,00 4,85 0,00
Cartilage intermediate layer protein 1 CILP-1 H 142 2,27 0,00 1,02 0,83 Early
K 102 1,27 0,00 1,06 0,46 -595
ARTICULAR JOINT LUBRICANTS DURING OSTEOARTHRITIS AND
RHEUMATOID ARTHRITIS DISPLAY ALTERED LEVELS AND
MOLECULAR SPECIES
M.K. Kosinska y, T.E. Ludwig z, G. Liebisch x, R. Zhang k, J. Wilhelm y,
U. Kaesser ¶, B. Ishaque y, M. Rickert y, T.A. Schmidt z, J. Steinmeyer y.
yUniv. of Giessen, Giessen, Germany; zUniv. of Calgary, Calgary, AB,
Canada; xUniv. of Regensburg, Regensburg, Germany; kRI-B-NT Res. Inst.
of Bioinformatics and Nanotechnology, Kiel, Germany; ¶ Internistisches
Praxiszentrum am Krankenhaus Balserische Stiftung, Giessen, Germany
Purpose: Hyaluronic acid (HA), lubricin, and phospholipids contribute
independently or together to the boundary lubrication of articular
joints that is provided by synovial ﬂuid (SF). In our present study wefocused on the two widespread joint diseases, osteoarthritis (OA) and
rheumatoid arthritis (RA). With use of sophisticated analytical methods
our study aimed to quantify the various molecular weight (MW) forms
of HA, lubricin, and all phospholipid species. Notably, we quantiﬁed
these lubricants for the ﬁrst time in parallel in knee SF from cohorts of
healthy donors, patients with early (eOA) or late (lOA) stage osteo-
arthritis, and patients with active RA.
Methods: Only patients fulﬁlling the inclusion criteria were included in
the study. This study was approved by the ethical review committee of
the Faculty of Medicine (Justus-Liebig-University of Giessen, Germany).
Cell- and cellular debris-free SF samples from unaffected controls, eOA,
lOA, and RA were used for this study. HA and lubricin levels were
measured by sandwich enzyme-linked immunosorbent assay (ELISA).
Electrospray ionization tandem mass spectrometry was used to quan-
tify phospholipid species, and fatty acids (FAs) were analyzed by gas
chromatography, coupled with mass spectrometry. The MW dis-
tribution of HA was determined by horizontal agarose gel electro-
phoresis followed by densitometry. One way ANOVA and Tukey’s
honestly signiﬁcant difference procedure were applied to determine
statistical signiﬁcant differences. P values of less than 0.05 were con-
sidered to be statistically signiﬁcant.
Results: We provide a novel, comprehensive overview of all lubricants
present in normal, OA and RA SF, namely HA, lubricin, and phospholi-
pids. Compared with control SF, the concentrations of HA and lubricin
were signiﬁcantly lower in eOA, lOA and RA SF, whereas those of
phospholipids were higher. Moreover, compared with control SF, the
MW distribution of HA shifted towards the lower range of below 1.1
MDa in eOA, lOA and RA SF. Notably, positive correlations were
observed in eOA SF between the concentrations of HA and lubricin, and
in lOA SF between the levels of HA and phospholipids. Moreover, in eOA
SF an elevated percentage of degraded HA was associated with lower
levels of lubricin. Remarkably, we noted distinct alterations between
cohorts with respect to the relative distribution of phospholipid species
and the degree of FA saturation and chain lengths of FAs.
Conclusions: This investigation reports for the ﬁrst time a compre-
hensive overview of all lubricants present in human SF, namely HA,
lubricin, and phospholipids. The levels, composition, and MW dis-
tribution of these lubricants vary with widespread joint diseases and
stage of OA. Thus, our study provides the framework to develop new
and optimal compounded lubricants able to reduce joint destruction.596
TARGETED PROTEOMICS OF HIP ARTICULAR CARTILAGE IN OA AND
FRACTURE PATIENTS
P. Onnerfjord, A. Khabut, S. Hosseininia, L. Dahlberg. Clinical Sci., Lund,
Sweden
Purpose: We have previously used quantitative proteomics for a
detailed study of different normal cartilage subtypes to increase our
knowledge of structure in relation to biology and function. In this work
we studied changes in protein abundance in hip cartilage between
osteoarthritis (OA) and fracture patients by using the increased sensi-
tivity of targeted proteomics technology.
Methods: Site matched femoral head articular cartilage from both OA
joint replacement patients selecting the macroscopically normal tissue
